Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 to ≤ 85 years
Lp(a) ≥ 200 nmol/L during screening
History of ASCVD as evidenced by history of either:
* Myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or
* Coronary revascularization with percutaneous coronary intervention AND at least 1 additional risk factor.
You may not be if
Severe renal dysfunction
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 x upper limit of normal (ULN), or total bilirubin (TBL) \> 2 x ULN during screening
History of hemorrhagic stroke
History of major bleeding disorder
Planned cardiac surgery or arterial revascularization
Severe heart failure
Current, recent, or planned lipoprotein apheresis
Previously received ribonucleic acid therapy specifically targeting Lp(a)
Clareo Health | Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
